Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apogee Therapeutics, Inc. - Common Stock (NQ: APGE ) 48.36 +0.54 (+1.13%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Apogee Therapeutics, Inc. - Common Stock Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases August 19, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results August 12, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors July 18, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD May 28, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics to Participate in Upcoming June Investor Conferences May 23, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases May 15, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results May 13, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference May 06, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases March 25, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million March 12, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering March 07, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering March 05, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results March 05, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of March 05, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 March 04, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire IPO watch 2024: Which new stocks will hit the market? January 08, 2024 Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. Via MarketBeat Topics Initial Public Offering Exposures Securities Market Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results November 13, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics to Participate in Upcoming November Investor Conferences October 30, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress September 27, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day September 14, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results August 28, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board August 21, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases August 07, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics to Participate in Upcoming August Investor Conferences August 02, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares July 18, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.